Literature DB >> 18068987

Validation of linear cerebral atrophy markers in multiple sclerosis.

H Butzkueven1, S C Kolbe, D J Jolley, J Y Brown, M J Cook, I A F van der Mei, P S Groom, J Carey, J Eckholdt, J P Rubio, B V Taylor, P J Mitchell, G F Egan, T J Kilpatrick.   

Abstract

Linear measures of cerebral ventricular enlargement may act as surrogate measures of cerebral atrophy in multiple sclerosis (MS). Linear atrophy markers were measured from routine MRI scans during a population survey of 171 Tasmanian MS patients and 91 healthy controls. Thirty-five Victorian MS clinic patients were recruited as a validation cohort with 14 of these re-assessed 4 years later. In the population survey, we measured three linear brain atrophy markers: inter-caudate distance (ICD), third ventricle width (TVW) and frontal horn width (FHW). TVW (OR 2.0, p=0.001) and ICD (OR 16.1, p<0.001) differentiated between MS cases and controls. In the validation study, we correlated the intercaudate ratio (ICR=ICD/brain width) and third ventricular ratio (TVR=TVW/brain width) with brain parenchymal volume. Cross-sectionally, ICR (R=-0.453, p<0.01) and TVR (R=-0.653, p<0.01) were correlated with brain parenchymal volume. Longitudinally, brain parenchymal volume loss was inversely correlated with increased ICD (R=-0.77, p<0.01) and TVW (R=-0.71, p<0.01). This study shows that ICD measurements obtained from clinical MRI scans are valid brain atrophy measures for use in monitoring MS progression.

Entities:  

Mesh:

Year:  2008        PMID: 18068987     DOI: 10.1016/j.jocn.2007.02.089

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  12 in total

1.  A simple brain atrophy measure improves the prediction of malignant middle cerebral artery infarction by acute DWI lesion volume.

Authors:  Christoph Beck; Anna Kruetzelmann; Nils D Forkert; Eric Juettler; Oliver C Singer; Martin Köhrmann; Jan F Kersten; Jan Sobesky; Christian Gerloff; Jens Fiehler; Peter D Schellinger; Joachim Röther; Götz Thomalla
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

2.  A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images.

Authors:  Juha Martola; Jakob Bergström; Sten Fredrikson; Leszek Stawiarz; Jan Hillert; Yi Zhang; Olof Flodmark; Anders Lilja; Anders Ekbom; Peter Aspelin; Maria Kristoffersen Wiberg
Journal:  Neuroradiology       Date:  2009-09-23       Impact factor: 2.804

3.  Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.

Authors:  Cathy J Jensen; Jim Stankovich; Anneke Van der Walt; Melanie Bahlo; Bruce V Taylor; Ingrid A F van der Mei; Simon J Foote; Trevor J Kilpatrick; Laura J Johnson; Ella Wilkins; Judith Field; Patrick Danoy; Matthew A Brown; Justin P Rubio; Helmut Butzkueven
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

Review 4.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

5.  A mechanism of rapidly reversible cerebral ventricular enlargement independent of tissue atrophy.

Authors:  Natalie M Zahr; Dirk Mayer; Torsten Rohlfing; Juan Orduna; Richard Luong; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Neuropsychopharmacology       Date:  2013-01-10       Impact factor: 7.853

6.  Neuroradiologic correlates of clinical disability and progression in the X-linked leukodystrophy Pelizaeus-Merzbacher disease.

Authors:  Jeremy J Laukka; Jeffrey A Stanley; James Y Garbern; Angela Trepanier; Grace Hobson; Tori Lafleur; Alexander Gow; John Kamholz
Journal:  J Neurol Sci       Date:  2013-08-30       Impact factor: 3.181

7.  Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability.

Authors:  Ashley D Radomski; Christopher Power; Scot E Purdon; Derek J Emery; Gregg Blevins; Kenneth G Warren; Esther Fujiwara
Journal:  BMC Neurol       Date:  2015-04-23       Impact factor: 2.474

8.  Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.

Authors:  Rasa Kizlaitienė; Gintaras Kaubrys; Nataša Giedraitienė; Naglis Ramanauskas; Jūratė Dementavičienė
Journal:  Med Sci Monit       Date:  2017-02-01

9.  Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Authors:  Alejandro Arenas-Pinto; Wolfgang Stöhr; Hans Rolf Jäger; Lewis Haddow; Amanda Clarke; Margaret Johnson; Fabian Chen; Alan Winston; Claudia Godi; Steffi Thust; Rita Trombin; Janet Cairns; Bhavana S Solanky; Xavier Golay; Nicholas I Paton
Journal:  Clin Infect Dis       Date:  2016-05-03       Impact factor: 9.079

Review 10.  Neurological manifestation of recreational fatal and near-fatal diethylene glycol poisonings: case series and review of literature.

Authors:  Yahia Zakaria Bashier Imam; Saadat Kamran; Hanfa Karim; Osama Elalamy; Tageldin Sokrab; Yasir Osman; Dirk Deleu
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.